Amgen requests expanded indication for denosumab

As expected (and as previously discussed on this site), Amgen has submitted a supplemental Biologics Licensing Application (sBLA) for denosumab (Xgeva®) for the prevention or the delay of the spread of prostate cancer to bone in men with castrate-resistant prostate cancer (CRPC). … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,142 other followers